Proteomics in Morbid Obesity After Bariatric Surgery (PROTOBESE)
Glycemic control is rapidly restored in patients with insulin resistance after bariatric surgery, in particular after the mal-absorptive one (i.e. Bilio-pancreatic diversion, BPD). To evaluate the mechanisms allowing restoration of insulin sensitivity after BPD the investigators aimed at identifying by using a proteomic approach plasma proteins or peptides that may be involved in the remarkably fast and explicit restoration of insulin sensitivity. In addition to the unbiased proteomics approach, a selection of recognized markers for metabolic control will be measured. These efforts all aim at an increased understanding of how insulin sensitivity is regulated and may provide novel ideas of how to treat insulin resistance and type 2-diabetes.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Identification of a Novel Factor(s) of Importance to Insulin Resistance -Repeated Blood Sampling Before and After Biliopancreatic Diversion|
- Proteomics [ Time Frame: 2 years ] [ Designated as safety issue: No ]used to identify plasma proteins or peptides that may be involved in the remarkably fast and explicit restoration of insulin sensitivity seen in morbidly obese patients with insulin resistance shortly after gastric bypass surgery by BPD.
- Insulin sensitivity and secretion and incretins [ Time Frame: 2 years ] [ Designated as safety issue: No ]Selection of recognized markers for metabolic control. Insulin secretion is measured by C-peptide deconvolution and insulin sensitivity by minimal modelling of glucose-insulin after a meal. Increatins will be measured too.
Biospecimen Retention: Samples Without DNA
Serum and plasma samples at fasting and after a meal
|Study Start Date:||June 2009|
|Study Completion Date:||July 2012|
|Primary Completion Date:||January 2011 (Final data collection date for primary outcome measure)|
Each subject is own control
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01151917
|Day Hospital of Metabolic Diseases, Catholic University|
|Rome, Italy, 00168|
|Principal Investigator:||Geltrude Mingrone, Professor||Catholic University of Rome|